Stem Cell Industry Puts Scotland in the Spotlight - Scotland's international acclaim for its stem cell research can be attributed to several factors, including a skilled workforce, government support,

ADVERTISEMENT

Stem Cell Industry Puts Scotland in the Spotlight
Scotland's international acclaim for its stem cell research can be attributed to several factors, including a skilled workforce, government support, and a top academic community.

BioPharm International


Stem cell research and manufacturing powerhouses, such as Stem Cell Sciences Ltd ( http://www.stemcellsciencesltd.com/), CXR Biosciences ( http://www.cxrbiosciences.com/), Invitrogen ( http://www.invitrogen.com/), Angel Biotechnology ( http://www.angelbio.com/), and Geron Corporation ( http://www.geron.com/), are prime examples of world-renowned companies conducting research in Scotland.

Also instrumental to Scotland's success is an organization that unites those interested in or conducting this type of research. The Scottish Stem Cell Network (SSCN, http://www.sscn.co.uk/), launched in 2003, brings together scientists and clinicians to improve the rate at which laboratory research translates into therapeutic benefits for patients. The SSCN works with the entire stem cell community in Scotland, including academic institutions and clinical and industry-based research groups, and also provides international organizations with easy access to stem cell researchers in Scotland. Another unique feature about the SSCN is the organization's role in engaging the general public to participate in open debates on issues deemed controversial with regards to this type of research.

Scotland is an ideal location in which to conduct stem cell research, with a powerful life sciences research and technology base and an equally supportive regulatory environment. Through advanced research led by globally respected stem cell experts and advanced facilities, Scotland is poised to continue to lead the way in the biomedical applications of cell biology.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here